Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's EDG-7500?
EDG-7500 is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase II program in Hypertrophic Cardiomyopathy. According to...
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's Sevasemten?
Sevasemten is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase III program in Becker Muscular Dystrophy. According...
Sevasemten by Edgewise Therapeutics for Becker Muscular Dystrophy: Likelihood of Approval
Sevasemten is under clinical development by Edgewise Therapeutics and currently in Phase III for Becker Muscular Dystrophy. According to GlobalData,...
EDG-7500 by Edgewise Therapeutics for Hypertrophic Cardiomyopathy: Likelihood of Approval
EDG-7500 is under clinical development by Edgewise Therapeutics and currently in Phase II for Hypertrophic Cardiomyopathy. According to GlobalData, Phase...
Sevasemten by Edgewise Therapeutics for Duchenne Muscular Dystrophy: Likelihood of Approval
Sevasemten is under clinical development by Edgewise Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's Sevasemten?
Sevasemten is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase III program in Becker Muscular Dystrophy. According...
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's EDG-7500?
EDG-7500 is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase II program in Hypertrophic Cardiomyopathy. According to...